Fueling Research, Feeding Discovery

New Products

Comprehensive assay kits for drug screening

  • Kit Solutions

    Kit Solutions

    AntBio offers mIHC kits, organoid culture kits, conventional and One-step ELISA assay kits, RNA/DNA/protein interaction kits, etc.

  • Cytokine Solutions

    Cytokine Solutions

    AntBio provides related cytokines of different cell types (organoids, stem cells, immune cells, etc.) with high purity and high activity verification

  • Target Protein Solutions

    Target Protein Solutions

    AntBio offers high performance target proteins in different research areas (antibody drugs, ADC drugs, CAR-T, small molecule drugs, etc.)

  • Loading Control

    Loading Control

    AntBio offers reliable and high-quality loading control antibodies, essential for accurate normalization in Western blotting and other protein quantification assays.

Featured Products

Essential Cytokines Special Offer

Cytokines as low as $29

15 Jul – 31 Aug, 2026

View Promotions

20% off for 5+ items

Enjoy 20% discount on 5 or more items storewide including OneStep ELISA Kits, mIHC Kits, IHC antibodies, Organoid Culture Kits, PTMs antibodies and so on.

Promo Period: 1 July 2026 to 31 Dec 2026

View Promotions

New Semester Launch | Spacial Biology

Discount Code: ANT2608@20

Promotion valid from 15 Aug to 31 Oct, 2026

View Promotions
bg

About Us

AntBio - Fueling Research, Feeding Discovery

AntBio is a biotechnology group company dedicated to serving life sciences, aiming to help scientists accelerate research and improve work efficiency. AntBio provides comprehensive and high-quality reagent tools for basic research, drug development, and diagnosis, including research grade antibodies, proteins, biochemical reagents, and assay kits. These research tools are widely used in different segments of life science research. The group company currently consists of three brands, Absin, Starter-Bio and UA-Bio.

About Us

50k

Happy Clients

100k

Products

70+

Doctor/Expert

20,000+

Publications

ARTICLES

Latest News

31 Aug 2026 by AntBio
Receptor Tyrosine Kinase‑Like Orphan Receptor 1 (ROR1): An Emerging Target for Tumour‑Immunology Basic‑Research Investigations

Receptor Tyrosine Kinase‑Li...

This article reviews ROR1 molecular‑domain architecture, non‑canonical Wnt signalling functions, expression profiles in haematological and solid‑tumour pre‑clinical models, and companion‑diagnostic antibody application considerations in oncology basic research. Researchers exploring ROR1‑targeted...

Receptor Tyrosine Kinase‑Li...

This article reviews ROR1 molecular‑domain architecture, non‑canonical Wnt signalling functions, expression profiles in haematological and solid‑tumour pre‑clinical models, and companion‑diagnostic...

View Details
Folate Receptor Alpha (FRα): Biomarker Antibodies Supporting Target‑Therapy Decision‑Making in Ovarian‑Cancer Basic Research

Folate Receptor Alpha (FRα): Biomarke...

This article reviews folate receptor‑alpha (FRα / FOLR1) molecular characteristics, oncogenic signalling functions, IHC biomarker‑scoring criteria and tumour‑heterogeneity‑related challenges in ovarian‑cancer basic‑research. Researchers investigating FRα‑targeted ADC pre‑clinical validation, tumour‑biomarker assessment...

Folate Receptor Alpha (FRα): Biomarke...

This article reviews folate receptor‑alpha (FRα / FOLR1) molecular characteristics, oncogenic signalling functions, IHC biomarker‑scoring criteria and tumour‑heterogeneity‑related challenges in...

View Details
CD19‑Targeted Antibody‑Drug Conjugates: Pre‑Clinical Research Perspectives for Relapsed/Refractory Diffuse Large B‑Cell Lymphoma

CD19‑Targeted Antibody‑Drug Conjugate...

This article reviews basic‑research knowledge of CD19‑targeted antibody‑drug conjugate loncastuximab tesirine (Lonca) for relapsed/refractory diffuse large B‑cell lymphoma. It covers CD19 molecular features, PBD‑dimer payload cytotoxic mechanism, LOTIS‑2 trial key...

CD19‑Targeted Antibody‑Drug Conjugate...

This article reviews basic‑research knowledge of CD19‑targeted antibody‑drug conjugate loncastuximab tesirine (Lonca) for relapsed/refractory diffuse large B‑cell lymphoma. It covers...

View Details
Claudin 18.2: An Emerging Target for Solid‑Tumour‑Oriented Basic‑Research Investigations

Claudin 18.2: An Emerging Target for ...

This article reviews Claudin 18.2 (CLDN18.2) molecular‑biology features, tumour‑associated expression patterns, pre‑clinical therapeutic exploration and remaining research bottlenecks in solid‑tumour basic‑research. Researchers studying gastric tumour biology, tight‑junction‑related oncogenic signalling and target‑agent...

Claudin 18.2: An Emerging Target for ...

This article reviews Claudin 18.2 (CLDN18.2) molecular‑biology features, tumour‑associated expression patterns, pre‑clinical therapeutic exploration and remaining research bottlenecks in solid‑tumour basic‑research....

View Details